Blue Owl Capital Holdings LP Invests $5.41 Million in ImageneBio, Inc. $IMA

Key Points

• Blue Owl Capital Holdings acquired 917,692 ImageneBio shares worth approximately $5.41 million, giving it an 8.62% stake and making the stock its 22nd-largest holding.
• Institutional ownership stands at 75%, with several other major investors recently initiating or expanding positions in the company.
• ImageneBio shares opened at $5.61, while analyst sentiment remains cautious: the consensus rating is Hold with a $30 average price target, despite the company beating quarterly EPS estimates.

Blue Owl Capital Holdings LP bought a new position in shares of ImageneBio, Inc. (NASDAQ:IMA - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 917,692 shares of the company's stock, valued at approximately $5,414,000. ImageneBio accounts for approximately 0.8% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 22nd biggest holding. Blue Owl Capital Holdings LP owned 8.62% of ImageneBio as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Barclays PLC boosted its holdings in shares of ImageneBio by 170.8% in the 4th quarter. Barclays PLC now owns 10,797 shares of the company's stock valued at $74,000 after acquiring an additional 6,810 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in ImageneBio during the fourth quarter valued at $76,000. Millennium Management LLC acquired a new position in ImageneBio during the fourth quarter valued at $79,000. T3 Companies LLC purchased a new stake in ImageneBio in the fourth quarter valued at $91,000. Finally, Jane Street Group LLC purchased a new stake in ImageneBio in the fourth quarter valued at $103,000. Hedge funds and other institutional investors own 75.00% of the company's stock.

Analyst Upgrades and Downgrades

IMA has been the topic of several analyst reports. Wall Street Zen downgraded ImageneBio from a "sell" rating to a "strong sell" rating in a research report on Sunday, May 17th. Wedbush restated an "underperform" rating on shares of ImageneBio in a research note on Monday, May 11th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of ImageneBio in a report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, ImageneBio presently has a consensus rating of "Hold" and an average target price of $30.00.

ImageneBio Trading Down 1.4%

Shares of IMA stock opened at $5.61 on Friday. The company has a market capitalization of $63.67 million, a P/E ratio of -1.22 and a beta of 0.76. The business's 50 day moving average is $5.79 and its two-hundred day moving average is $5.87. ImageneBio, Inc. has a 12-month low of $3.94 and a 12-month high of $14.34.

ImageneBio (NASDAQ:IMA - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.90) by $0.27. On average, research analysts predict that ImageneBio, Inc. will post -3.07 earnings per share for the current fiscal year.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source